Segall Bryant & Hamill LLC Boosts Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Segall Bryant & Hamill LLC boosted its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 11.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,350,746 shares of the medical research company’s stock after acquiring an additional 236,924 shares during the period. Segall Bryant & Hamill LLC’s holdings in NeoGenomics were worth $22,309,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. CWM LLC boosted its stake in NeoGenomics by 42.6% during the first quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock worth $60,000 after acquiring an additional 1,883 shares in the last quarter. Principal Financial Group Inc. boosted its stake in NeoGenomics by 2.7% during the first quarter. Principal Financial Group Inc. now owns 639,411 shares of the medical research company’s stock worth $6,068,000 after acquiring an additional 16,562 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in NeoGenomics during the first quarter worth about $178,000. Allspring Global Investments Holdings LLC boosted its stake in NeoGenomics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 33,461 shares of the medical research company’s stock worth $318,000 after acquiring an additional 11,733 shares in the last quarter. Finally, HighMark Wealth Management LLC boosted its stake in NeoGenomics by 28.7% during the first quarter. HighMark Wealth Management LLC now owns 124,600 shares of the medical research company’s stock worth $1,182,000 after acquiring an additional 27,800 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Trading Down 3.9%

Shares of NASDAQ NEO opened at $6.90 on Wednesday. The firm’s 50 day moving average price is $7.48 and its 200-day moving average price is $10.20. The company has a market cap of $888.03 million, a PE ratio of -11.31 and a beta of 1.63. NeoGenomics, Inc. has a 52-week low of $6.08 and a 52-week high of $19.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.95 and a current ratio of 2.05.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.54% and a negative return on equity of 2.21%. The company had revenue of $168.04 million for the quarter, compared to analysts’ expectations of $171.38 million. During the same period in the previous year, the firm earned ($0.02) earnings per share. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. On average, equities research analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Insider Activity

In related news, CEO Anthony P. Zook acquired 18,900 shares of the firm’s stock in a transaction dated Tuesday, May 6th. The stock was purchased at an average cost of $7.88 per share, with a total value of $148,932.00. Following the completion of the acquisition, the chief executive officer directly owned 18,900 shares of the company’s stock, valued at approximately $148,932. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David Brian Perez acquired 10,000 shares of the firm’s stock in a transaction dated Monday, May 5th. The shares were bought at an average cost of $7.63 per share, with a total value of $76,300.00. Following the completion of the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $76,300. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 70,600 shares of company stock valued at $550,438 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

NEO has been the topic of several research reports. Leerink Partnrs lowered shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 30th. Piper Sandler set a $12.00 price objective on shares of NeoGenomics and gave the stock an “overweight” rating in a research note on Tuesday, May 6th. Needham & Company LLC dropped their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Leerink Partners downgraded shares of NeoGenomics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $25.00 to $9.00 in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group dropped their target price on shares of NeoGenomics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.83.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.